Worldwide Study Finder

Phase 3Active, not recruitingINTERVENTIONAL

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

ClinicalTrials.gov · NCT04484818 · Registry updated: 2026-07-28

Condition / research focus: Prostate Carcinoma
Sponsor: ECOG-ACRIN Cancer Research Group
Countries with listed sites: United States
Registry dates and results: Start: 2021-03-01. Completion: 2028-05-31 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Darolutamide (drug) — also listed as: Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, ODM 201, ODM-201
Goserelin Acetate (drug) — also listed as: ZDX, Zoladex
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Placebo Administration (drug)
Quality-of-Life Assessment (other) — also listed as: Quality of Life Assessment

Phase 2Not yet recruitingINTERVENTIONAL

Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.

ClinicalTrials.gov · NCT07730151 · Registry updated: 2026-07-28

Condition / research focus: Prostate Cancer; Prostate; Prostate Cancer Patients
Sponsor: RenJi Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-08-01. Completion: 2031-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Darolutamide (drug)
docetaxel (drug)
ADT (drug)

Where the study takes place — 0 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

ClinicalTrials.gov · NCT06378866 · Registry updated: 2026-07-20

Condition / research focus: Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2024-06-03. Completion: 2031-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (21)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Abiraterone (drug) — also listed as: Abiraterone acetate, CB-7598, CB7598, Zytiga
Apalutamide (drug) — also listed as: ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927
Biospecimen Collection (procedure) — also listed as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Bone Scan (procedure) — also listed as: Bone Scintigraphy
Computed Tomography (procedure) — also listed as: CAT, CAT Scan, Computed Axial Tomography (CAT), Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
Darolutamide (drug) — also listed as: Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201
Degarelix (drug) — also listed as: ASP3550, FE200486, Firmagon
Enzalutamide (drug) — also listed as: ASP9785, MDV3100, Xtandi
Goserelin (drug) — also listed as: ICI-118630
Histrelin (drug)
Leuprolide (drug) — also listed as: Leuprorelin
Magnetic Resonance Imaging (procedure) — also listed as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, Nuclear Magnetic Resonance (NMR) Imaging, NMRI, Nuclear Magnetic Resonance Imaging (NMRI), sMRI, Structural MRI (sMRI), NMR Imaging
Patient Observation (other) — also listed as: Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting
Positron Emission Tomography (procedure) — also listed as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography (PET), Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
Prednisone (drug) — also listed as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
Questionnaire Administration (other)
Relugolix (drug) — also listed as: N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385
Stereotactic Body Radiation Therapy (radiation) — also listed as: SABR, SBRT, Stereotactic Ablative Body Radiation (SABR), Stereotactic Ablative Body Radiation Therapy
Triptorelin (drug) — also listed as: 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, AY25650, CL-118,532, CL118532, Detryptoreline
Radiation Therapy (radiation) — also listed as: Cancer Radiotherapy, Irradiation, RADIATION, Radiotherapeutics, RADIOTHERAPY
Image-Guided Therapy (procedure) — also listed as: Image Guided Therapy

Where the study takes place — 3 listed sites

Mayo Clinic in Arizona
Phoenix, Arizona, United States
Site recruitment: Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, United States
Site recruitment: Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

ClinicalTrials.gov · NCT05493709 · Registry updated: 2026-07-20

Condition / research focus: Puberty; Precocious, Central
Sponsor: Foresee Pharmaceuticals Co., Ltd.
Countries with listed sites: China · Puerto Rico · Taiwan · United States
Registry dates and results: Start: 2023-06-02. Completion: 2026-05-24 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide (drug)

Where the study takes place — 41 listed sites

Arizona University
Tucson, Arizona, United States
Site recruitment: Not reported
Rady Children's Hospital- San Diego
San Diego, California, United States
Site recruitment: Not reported
Nemours Children's Health Center
Jacksonville, Florida, United States
Site recruitment: Not reported
Johns Hopkins - All Children's Hospital
St. Petersburg, Florida, United States
Site recruitment: Not reported
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Site recruitment: Not reported
Indiana University
Indianapolis, Indiana, United States
Site recruitment: Not reported
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported
Cook Children's
Fort Worth, Texas, United States
Site recruitment: Not reported
Virginia University
Charlottesville, Virginia, United States
Site recruitment: Not reported
Multicare Health System
Tacoma, Washington, United States
Site recruitment: Not reported
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Site recruitment: Not reported
Children's Hospital affiliated to Capital Institute of Pediatrics
Beijing, Chaoyang District, China
Site recruitment: Not reported
The first Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Site recruitment: Not reported
Pearl River Hospital, Southern Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College of HUST
Wuhan, Hubei, China
Site recruitment: Not reported
Wuhan Children's Hospital, Tongji Medical College of HUST
Wuhan, Hubei, China
Site recruitment: Not reported
Hunan Children's Hospital
Changsha, Hunan, China
Site recruitment: Not reported
Children's Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Not reported
Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China
Site recruitment: Not reported
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
Children's Hospital of Shanxi
Taiyuan, Shanxi, China
Site recruitment: Not reported
Chengdu Women's and Children's Central Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not reported
The First Hospital of Jiaxing Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China
Site recruitment: Not reported
Ningbo Women & Children's Hospital
Ningbo, Zhejiang, China
Site recruitment: Not reported
Beijing Children's Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported
Children's Hospital of Fudan University
Shanghai, China
Site recruitment: Not reported
Children's Hospital of Shanghai
Shanghai, China
Site recruitment: Not reported
Shanghai Children's Medical Center
Shanghai, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, China
Site recruitment: Not reported
University Pediatric Hospital
San Juan, Puerto Rico
Site recruitment: Not reported
Changhua Christian Hospital
Changhua, Taiwan
Site recruitment: Not reported
Chang Gung Memorial Hospital-Kaohsiung branch
Kaohsiung City, Taiwan
Site recruitment: Not reported
China Medical University Hospital
Taichung, Taiwan
Site recruitment: Not reported
National Cheng Kung University Hospital
Tainan, Taiwan
Site recruitment: Not reported
Mackay Memorial Hospital
Taipei, Taiwan
Site recruitment: Not reported
LinKou Chang-Gung Memorial Hospital (CGMH-LK)
Taoyuan City, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Kisspeptin Administration Subcutaneously to Patients With IHH

ClinicalTrials.gov · NCT05896293 · Registry updated: 2026-07-13

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Stephanie B. Seminara, MD
Countries with listed sites: United States
Registry dates and results: Start: 2023-02-03. Completion: 2028-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

kisspeptin 112-121 (drug) — also listed as: metastin 45-54
leuprolide acetate (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

ClinicalTrials.gov · NCT05498272 · Registry updated: 2026-07-10

Condition / research focus: Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
Sponsor: Rana McKay, MD
Countries with listed sites: United States
Registry dates and results: Start: 2023-02-01. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Olaparib (drug) — also listed as: Lynparza
LHRH agonist (drug) — also listed as: Goserelin, Triptorelin, Leuprolide

Where the study takes place — 6 listed sites

University of California San Diego - Moores Cancer Center
La Jolla, California, United States
Site recruitment: Not reported
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Columbia University Irving Medical Center
New York, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Not reported
Penn Medicine Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

ClinicalTrials.gov · NCT07142967 · Registry updated: 2026-07-10

Condition / research focus: Intraprostatic Prostate Cancer
Sponsor: NYU Langone Health
Countries with listed sites: United States
Registry dates and results: Start: 2025-08-15. Completion: 2030-08-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Stereotactic Body Radiation Therapy (SBRT) (radiation)
Androgen Deprivation Therapy (ADT) (drug)

Where the study takes place — 1 listed sites

NYU Langone Health
New York, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4Active, not recruitingINTERVENTIONAL

Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

ClinicalTrials.gov · NCT06926933 · Registry updated: 2026-07-08

Condition / research focus: CPP
Sponsor: HanAll BioPharma Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2024-12-12. Completion: 2027-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Eligard® 45 mg (drug)

Where the study takes place — 9 listed sites

Korea University Ansan Hospital
Ansan, South Korea
Site recruitment: Not reported
Jeonbuk National University Hospital
Jeonju, South Korea
Site recruitment: Not reported
Chosun University Hospital
Kwangju, South Korea
Site recruitment: Not reported
Seoul National University Bundang Hospital
Seongnam, South Korea
Site recruitment: Not reported
Asan Medical Center
Seoul, South Korea
Site recruitment: Not reported
Gangnam Severance Hospital
Seoul, South Korea
Site recruitment: Not reported
Kangdong Sacred Heart Hospital
Seoul, South Korea
Site recruitment: Not reported
Kyung Hee University Hospital At Gangdong
Seoul, South Korea
Site recruitment: Not reported
Ajou University Medical Center
Suwon, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableActive, not recruitingINTERVENTIONAL

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

ClinicalTrials.gov · NCT05628363 · Registry updated: 2026-07-02

Condition / research focus: Prostate Cancer; Cancer of the Prostate
Sponsor: Washington University School of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2023-01-18. Completion: 2030-07-25 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ethos Varian treatment system (device)
Adaptive stereotactic body radiotherapy (radiation) — also listed as: SBRT
Androgen deprivation therapy (drug) — also listed as: ADT

Where the study takes place — 1 listed sites

Washington University School of Medicine
St Louis, Missouri, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

ClinicalTrials.gov · NCT00175383 · Registry updated: 2026-07-02

Condition / research focus: Prostate Cancer
Sponsor: University of British Columbia
Countries with listed sites: Canada
Registry dates and results: Start: 2004-06. Completion: 2008-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

luteinizing hormone-releasing hormone (LHRH) short acting or long acting (drug)

Where the study takes place — 1 listed sites

BC Cancer Agency - Vancouver Island Centre
Victoria, British Columbia, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov · NCT02346253 · Registry updated: 2026-07-02

Condition / research focus: Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2015-01-13. Completion: 2026-05-17 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Internal Radiation Therapy (radiation) — also listed as: Brachytherapy, Internal Radiation, Internal Radiation Brachytherapy, Radiation Brachytherapy
Bicalutamide (drug) — also listed as: CDX
Leuprolide Acetate (drug) — also listed as: A-43818
Goserelin Acetate (drug) — also listed as: ICI-118630, ZDX, Zoladex
Triptorelin Pamoate (drug) — also listed as: Pamorelin, Trelstar
Degarelix (drug) — also listed as: FE200486, Firmagon
Laboratory Biomarker Analysis (other)
Quality-of-Life Assessment (other) — also listed as: Quality of Life Assessment

Where the study takes place — 1 listed sites

Stanford University, School of Medicine
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

ClinicalTrials.gov · NCT07313241 · Registry updated: 2026-06-30

Condition / research focus: Prostate Cancer
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2025-11-14. Completion: 2030-11-14 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Prostate Fossa Radiotherapy (radiation)
Pelvic nodal Radiotherapy (radiation)
Androgen Deprivation Therapy (ADT) (drug)

Where the study takes place — 1 listed sites

UT Southwestern Medical Center-Dallas
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

ClinicalTrials.gov · NCT07158021 · Registry updated: 2026-06-23

Condition / research focus: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma
Sponsor: University of Michigan Rogel Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2026-01-22. Completion: 2028-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biospecimen Collection (procedure) — also listed as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Electronic Health Record Review (other)
Goserelin (drug) — also listed as: ICI-118630
Leuprolide (drug) — also listed as: Leuprorelin
Questionnaire Administration (other)

Where the study takes place — 1 listed sites

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

ClinicalTrials.gov · NCT07477626 · Registry updated: 2026-06-16

Condition / research focus: Prostate Cancer (Post Prostatectomy); Radiotherapy; Image-Guided; Prostate Cancer Non-Metastatic; Androgen Deprivation Therapy; Lymph Node Positive
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2026-03-20. Completion: 2038-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Androgen Deprivation Therapy (ADT) (drug)
radiotherapy (radiation)

Where the study takes place — 13 listed sites

Dongguan People's Hospital
Dongguan, Guangdong, China
Site recruitment: Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site recruitment: Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not yet recruiting
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not yet recruiting
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Site recruitment: Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China
Site recruitment: Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Site recruitment: Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not yet recruiting
Beijing Hospital
Beijing, China
Site recruitment: Recruiting
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Site recruitment: Not yet recruiting
Peking University First Hospital
Beijing, China
Site recruitment: Recruiting
Peking University Third Hospital
Beijing, China
Site recruitment: Not yet recruiting
The First Affiliated Hospital of Naval Medical University
Shanghai, China
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

ClinicalTrials.gov · NCT05605964 · Registry updated: 2026-06-15

Condition / research focus: Prostate Cancer
Sponsor: Sumitomo Pharma America, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2023-01-28. Completion: 2024-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Relugolix (drug) — also listed as: ORGOVYX, TAK-385, MVT-601, RVT-601, T-1331285
Leuprolide Acetate (drug) — also listed as: Leuprolide

Where the study takes place — 108 listed sites

Urology Associates of Mobile
Mobile, Alabama, United States
Site recruitment: Not reported
Arizona Urology Specialists, PLLC
Tucson, Arizona, United States
Site recruitment: Not reported
Arkansas Urology
Little Rock, Arkansas, United States
Site recruitment: Not reported
Genesis Research, LLC Satellite
Downey, California, United States
Site recruitment: Not reported
Orange Coast Memorial Medical Center
Fountain Valley, California, United States
Site recruitment: Not reported
Genesis Research , LLC
Los Alamitos, California, United States
Site recruitment: Not reported
Tower Urology
Los Angeles, California, United States
Site recruitment: Not reported
Pacific Cancer Care
Monterey, California, United States
Site recruitment: Not reported
Tri Valley Urology Medical Group
Murrieta, California, United States
Site recruitment: Not reported
Tri Valley Urology Medical Group Satellite
Murrieta, California, United States
Site recruitment: Not reported
San Bernadino Urological Associates Medical Group
San Bernardino, California, United States
Site recruitment: Not reported
Genesis Research, LLC
San Diego, California, United States
Site recruitment: Not reported
Genesis Research, LLC Satellite
Sherman Oaks, California, United States
Site recruitment: Not reported
Tri Valley Urology Medical Group Satellite
Temecula, California, United States
Site recruitment: Not reported
Genesis Research, LLC Satellite
Torrance, California, United States
Site recruitment: Not reported
Genesis Research, LLC Satellite
Torrance, California, United States
Site recruitment: Not reported
Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Urologic Surgeons of Washington
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Advanced Urology Institute
Daytona Beach, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC Satellite
Jacksonville, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC Satellite
Jacksonville, Florida, United States
Site recruitment: Not reported
Lake City Cancer Center, LLC
Lake City, Florida, United States
Site recruitment: Not reported
SG Research LLC
Miami, Florida, United States
Site recruitment: Not reported
Florida Urology Partners, LLP Satellite
Tampa, Florida, United States
Site recruitment: Not reported
Florida Urology Partners, LLP
Tampa, Florida, United States
Site recruitment: Not reported
Florida Urology Partners, LLP Satellite
Tampa, Florida, United States
Site recruitment: Not reported
Augusta University
Augusta, Georgia, United States
Site recruitment: Not reported
Georgia Cancer Center Satellite
Augusta, Georgia, United States
Site recruitment: Not reported
St. Luke's Regional Medical Center Satellite
Boise, Idaho, United States
Site recruitment: Not reported
St. Luke's Regional Medical Center
Boise, Idaho, United States
Site recruitment: Not reported
St. Luke's Cancer Institute - Fruitland Satellite
Fruitland, Idaho, United States
Site recruitment: Not reported
St. Luke's Cancer Institute - Meridian Satellite
Meridian, Idaho, United States
Site recruitment: Not reported
St. Luke's Meridian Medical Center Satellite
Meridian, Idaho, United States
Site recruitment: Not reported
St. Luke's Cancer Institute - Nampa Satellite
Nampa, Idaho, United States
Site recruitment: Not reported
St. Luke's Nampa Medical Center Satellite
Nampa, Idaho, United States
Site recruitment: Not reported
St. Luke's Cancer Institute Satellite
Twin Falls, Idaho, United States
Site recruitment: Not reported
St. Luke's Magic Valley Medical Center Satellite
Twin Falls, Idaho, United States
Site recruitment: Not reported
Illinois CancerCare - Bloomington Satellite
Bloomington, Illinois, United States
Site recruitment: Not reported
Northwestern University
Chicago, Illinois, United States
Site recruitment: Not reported
Swedish Hospital Satellite
Chicago, Illinois, United States
Site recruitment: Not reported
Associated Urological Specialists
Chicago Ridge, Illinois, United States
Site recruitment: Not reported
NorthShore University Health System - Evanston Hospital
Evanston, Illinois, United States
Site recruitment: Not reported
Illinois CancerCare - Galesburg Satellite
Galesburg, Illinois, United States
Site recruitment: Not reported
NorthShore University Health System - Glenbrook Hospital Ambulatory Care Center Satellite
Glenview, Illinois, United States
Site recruitment: Not reported
NorthShore University Health System - Highland Park Hospital Ambulatory Care Center Satellite
Highland Park, Illinois, United States
Site recruitment: Not reported
Comprehensive Urologic Care
Lake Barrington, Illinois, United States
Site recruitment: Not reported
Advanced Urology Associates
New Lenox, Illinois, United States
Site recruitment: Not reported
Illinois CancerCare - Ottawa Satellite
Ottawa, Illinois, United States
Site recruitment: Not reported
Illinois CancerCare - Pekin Satellite
Pekin, Illinois, United States
Site recruitment: Not reported
Illinois CancerCare, P.C.
Peoria, Illinois, United States
Site recruitment: Not reported
Illinois CancerCare - Peru Satellite
Peru, Illinois, United States
Site recruitment: Not reported
Illinois CancerCare - Washington Satellite
Washington, Illinois, United States
Site recruitment: Not reported
Urology of Indiana, LLC Satellite
Carmel, Indiana, United States
Site recruitment: Not reported
Urology of Indiana, LLC
Greenwood, Indiana, United States
Site recruitment: Not reported
IU Health Arnett Cancer Center
Lafayette, Indiana, United States
Site recruitment: Not reported
IU Health Ball Memorial Hospital Satellite
Muncie, Indiana, United States
Site recruitment: Not reported
Adult and Pediatric Urology P.C. Satellite
Council Bluffs, Iowa, United States
Site recruitment: Not reported
Greater Regional Medical Center
Creston, Iowa, United States
Site recruitment: Not reported
Wichita Urology Group Satellite
Wichita, Kansas, United States
Site recruitment: Not reported
Wichita Urology Group Satellite
Wichita, Kansas, United States
Site recruitment: Not reported
Wichita Urology Group
Wichita, Kansas, United States
Site recruitment: Not reported
Comprehensive Urology
Royal Oak, Michigan, United States
Site recruitment: Not reported
Michigan Institute of Urology
Troy, Michigan, United States
Site recruitment: Not reported
Lake Regional Health System
Osage Beach, Missouri, United States
Site recruitment: Not reported
Specialty Clinical Research of St. Louis
St Louis, Missouri, United States
Site recruitment: Not reported
Urology of St. Louis Satellite
St Louis, Missouri, United States
Site recruitment: Not reported
St. Vincent Healthcare Satellite
Billings, Montana, United States
Site recruitment: Not reported
St. Vincent - Frontier Cancer Center
Billings, Montana, United States
Site recruitment: Not reported
Adult and Pediatric Urology P.C.
Omaha, Nebraska, United States
Site recruitment: Not reported
Capital Health Medical Center - Hopewell
Pennington, New Jersey, United States
Site recruitment: Not reported
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Site recruitment: Not reported
Albany Medical College
Albany, New York, United States
Site recruitment: Not reported
Associated Medical Professionals of NY, PLLC
Syracuse, New York, United States
Site recruitment: Not reported
Oncology Specialists of Charlotte
Charlotte, North Carolina, United States
Site recruitment: Not reported
Associated Urologists of North Carolina
Raleigh, North Carolina, United States
Site recruitment: Not reported
Altru Cancer Center
Grand Forks, North Dakota, United States
Site recruitment: Not reported
Altru Health System Satellite
Grand Forks, North Dakota, United States
Site recruitment: Not reported
Altru Professional Center Satellite
Grand Forks, North Dakota, United States
Site recruitment: Not reported
University Hospitals Seidman Cancer Center at UH Avon Health Center Satellite
Avon, Ohio, United States
Site recruitment: Not reported
TriState Urologic Services PSC Inc.
Cincinnati, Ohio, United States
Site recruitment: Not reported
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Site recruitment: Not reported
Central Ohio Urology Group Satellite
Gahanna, Ohio, United States
Site recruitment: Not reported
Central Ohio Urology Group
Gahanna, Ohio, United States
Site recruitment: Not reported
University Hospitals Seidman Cancer Center at UH Mentor Health Center Satellite
Mentor, Ohio, United States
Site recruitment: Not reported
Helios CR, LLC
Middleburg Heights, Ohio, United States
Site recruitment: Not reported
UH Minoff Health Center at Chagrin Highlands
Orange, Ohio, United States
Site recruitment: Not reported
MidLantic Urology
Bala-Cynwyd, Pennsylvania, United States
Site recruitment: Not reported
Keystone Urology Specialists
Lancaster, Pennsylvania, United States
Site recruitment: Not reported
Guthrie Medical Group, PC
Sayre, Pennsylvania, United States
Site recruitment: Not reported
Robert Packer Hospital Satellite
Sayre, Pennsylvania, United States
Site recruitment: Not reported
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Site recruitment: Not reported
Lowcountry Urology Clinics
North Charleston, South Carolina, United States
Site recruitment: Not reported
Urology Associates, P.C.
Nashville, Tennessee, United States
Site recruitment: Not reported
Valley Cancer Associates
Harlingen, Texas, United States
Site recruitment: Not reported
Houston Metro Urology CRC, LLC
Houston, Texas, United States
Site recruitment: Not reported
Urology San Antonio Clinical Trials
San Antonio, Texas, United States
Site recruitment: Not reported
The Urology Place
San Antonio, Texas, United States
Site recruitment: Not reported
Logan Regional Hospital Satellite
Logan, Utah, United States
Site recruitment: Not reported
Intermountain Medical Center Satellite
Murray, Utah, United States
Site recruitment: Not reported
McKay-Dee Hospital Satellite
Ogden, Utah, United States
Site recruitment: Not reported
Utah Valley Hospital
Provo, Utah, United States
Site recruitment: Not reported
St. George Regional Hospital Satellite
St. George, Utah, United States
Site recruitment: Not reported
Potomac Urology Center, PC
Alexandria, Virginia, United States
Site recruitment: Not reported
Virginia Urology
Richmond, Virginia, United States
Site recruitment: Not reported
Urology of Virginia
Virginia Beach, Virginia, United States
Site recruitment: Not reported
Potomac Urology Satellite
Woodbridge, Virginia, United States
Site recruitment: Not reported
Spokane Urology
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

ClinicalTrials.gov · NCT00329043 · Registry updated: 2026-06-12

Condition / research focus: Prostate Cancer
Sponsor: M.D. Anderson Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2006-05-15. Completion: 2027-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LHRH Agonist (drug) — also listed as: Lupron, Leuprolide
Sunitinib Malate (drug) — also listed as: SU011248
Radical Prostatectomy (procedure)

Where the study takes place — 1 listed sites

University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.

ClinicalTrials.gov · NCT07610733 · Registry updated: 2026-05-28

Condition / research focus: Breast Cancer
Sponsor: Fudan University
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-06-01. Completion: 2030-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

1-month GnRH (drug)
3-month GnRH (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

ClinicalTrials.gov · NCT03555578 · Registry updated: 2026-05-22

Condition / research focus: Spinal and Bulbar Muscular Atrophy
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2017-11-02. Completion: 2026-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin Acetate (drug) — also listed as: Leuplin SR for Injection Kit 11.25 mg

Where the study takes place — 1 listed sites

Takeda Selected Site
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2Active, not recruitingINTERVENTIONAL

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

ClinicalTrials.gov · NCT04194554 · Registry updated: 2026-05-01

Condition / research focus: Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2020-11-06. Completion: 2029-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Niraparib (drug)
Leuprolide (drug)
Abiraterone Acetate (drug)
Stereotactic body radiotherapy (SBRT) (radiation) — also listed as: Ultra-hypofractionated radiotherapy

Where the study takes place — 6 listed sites

University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
Cornell University
New York, New York, United States
Site recruitment: Not reported
Weill Cornell Medicine
New York, New York, United States
Site recruitment: Not reported
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
Site recruitment: Not reported
University of Texas Southwestern
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov · NCT07553988 · Registry updated: 2026-04-28

Condition / research focus: Metastatic Castration-resistant Prostate Cancer
Sponsor: R-Pharm International, LLC
Countries with listed sites: Russia
Registry dates and results: Start: 2024-10-24. Completion: 2027-05-09 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

RS-113, 160 mg (drug) — also listed as: L01069
RS-113, 240 mg (drug) — also listed as: L01069
RS-113, 320 mg (drug) — also listed as: L01069
Abiraterone (drug)
Prednisolone (drug)
Androgen deprivation therapy (ADT) (drug)

Where the study takes place — 16 listed sites

State Budgetary Healthcare Institution of the Arkhangelsk Region "Arkhangelsk Oncology Dispensary"
Arkhangelsk, Russia
Site recruitment: Not reported
Moscow City Clinical Oncology Hospital No. 62 of the Moscow Department of Healthcare
Istra, Russia
Site recruitment: Not reported
Ivanovo Regional Oncology Dispensary
Ivanovo, Russia
Site recruitment: Not reported
Kaluga Regional Clinical Oncology Dispensary
Kaluga, Russia
Site recruitment: Not reported
State Budgetary Healthcare Institution "Leningrad Regional Clinical Hospital"
Kuz'molovskiy, Russia
Site recruitment: Not reported
Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow Healthcare Department
Moscow, Russia
Site recruitment: Not reported
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Moscow, Russia
Site recruitment: Not reported
Federal State Autonomous Institution "National Medical Research Center 'Medical and Rehabilitation Center'" of the Ministry of Health of the Russian Federation
Moscow, Russia
Site recruitment: Not reported
Research Lab LLC
Moscow, Russia
Site recruitment: Not reported
Joint-Stock Company "Medsi Group of Companies"
Moscow, Russia
Site recruitment: Not reported
LLC MSCh "Klinitsist-Klinika Pretor"
Novosibirsk, Russia
Site recruitment: Not reported
Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of Saint-Petersburg"
Saint Petersburg, Russia
Site recruitment: Not reported
City Clinical Oncology Dispensary (Saint Petersburg)
Saint Petersburg, Russia
Site recruitment: Not reported
Siberian State Medical University
Tomsk, Russia
Site recruitment: Not reported
Multidisciplinary Clinical Medical Center "Medical City"
Tyumen, Russia
Site recruitment: Not reported
State Institution of Healthcare of Yaroslavl Region "Regional Oncology Hospital"
Yaroslavl, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Explore the world’s study registries

Worldwide

Africa

Americas

Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Kisspeptin Administration Subcutaneously to Patients With IHH

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.

Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Asia

Middle East

Europe

Oceania